Application value of human papillomavirus DNA detection and ThinPrep liquidbased cytology testing in cervical lesions

Abstract:

ObjectiveTo evaluate the application value of  highrisk  human papillomavirus (HRHPV) DNA detection and ThinPrep liquidbased cytology testing（TCT）in cervical disease screening.  MethodsCervical specimens of women with cervical lesions in a hospital between October 2012 and December 2013 were taken and performed human papillomavirus DNA genotyping (HPV DNA) and ThinPrep liquidbased cytology testing(TCT). Positive patients were performed colposcopy pathological detection. HPV DNA positive rates among different TCT groups, and different cervical lesion groups were compared, the sensitivity and specificity of TCT and HPV DNA detection, as well as differences between  separate  and joint detection were also compared. ResultsThe positive rate of HPV DNA was 28.07% (1 045/3 723), most were HRHPV (21.57%, n=803), the major HRHPV genotypes were HPV 16,58,52,and 18 type. HRHPV positive rates were statistically different among different age groups（χ2=31.74，P＜0.001） , positive rate was highest in 20-30 year old age group . Positive rate of TCT was 13.46% (n=501), a total of 971 patients were performed pathological detection, 293 were positive. Patients were divided according to different TCT and different lesion type, χ2 testing of HRHPV DNA positive rate showed that positive rate of HRHPV had a increasing tendency with the increase in severity of diseases(all P<0.01). Pathological detection was as a gold standard , the sensitivity of HRHPV DNA and TCT  was 90.44％(265/293) and 85.32％(250/293)  respectively, the sensitivity of joint HRHPV DNA detection and TCT  was 95.90％. In positive pathological group, the detection rate of TCT and HRHPV DNA was 85.32％ and 90.44%, respectively, joint detection rate was 95.90％, the difference among three groups was significant (χ2=18.185，P<0.001）. Joint detection rate was higher than separate detection rate of TCT or HPV DNA. ConclusionHPV DNA detection is a useful supplement for cervical cancer screening, HPV DNA detection combined with TCT can reduce the misdiagnosis rate.